Tag:

AstraZeneca

Latest Headlines

Latest Headlines

Ardelyx buys troubled sodium drug back from AstraZeneca with PhIII in sight

Moving on from a costly Phase II setback for its lead drug, Ardelyx is looking to go it alone without AstraZeneca, buying out its former partner and pressing forward into late-stage development.

Leading Japan drug firms team up with AZ on parasitic disease research

Japan's Eisai, Shinogi and Takeda Pharmaceutical have teamed up with U.K.-based AstraZeneca on a broad R&D effort to find treatments for insect-borne parasitic diseases Chagas and leishmaniasis.

Bristol-Myers fires off a lawsuit to sideline R&D defector headed to rival AstraZeneca

Bristol-Myers Squibb is the leader right now in immuno-oncology and checkpoint inhibitors and it clearly is willing to get aggressive about defending that early edge. In a move that shows just how competitive this blockbuster field has become, the big biotech wants to force one of its ex-R&D leaders in I/O to sit out the next year rather than go to work for a major league rival.

Doctors look for a single test to identify best immunotherapy drugs for cancer patients

With a new crop of cancer immunotherapy drugs that offer the hope of battling forms of cancer previously thought untreatable, researchers and physicians are looking for tests that can better pinpoint which patients respond to each of the treatments.

AstraZeneca's Definiens rolls out biomarker data service

Definiens introduced a suite of services to help companies gather data from tissue samples and use the resource to identify potential companion diagnostics.

AZ in distribution pact with Dr. Reddy's to extend reach in India

AstraZeneca Pharma India has signed up Dr. Reddy's Laboratories to distribute its diabetes medicines Riax and Riax-M in India as domestic and foreign companies look for advantages in a crucial and sharply competitive market where generic activity is on the rise.

UPDATED: Clovis boasts promising ovarian cancer data as lung cancer results fade

Over the weekend, Clovis Oncology took another big step toward its near-term goal of launching commercial operations, with plans to take pharma giant AstraZeneca head-on with two key franchise showdowns. The Boulder, CO-based biotech posted positive data from a mid-stage study of its ovarian cancer drug rucaparib at ASCO, while adding new--though less impressive--data to back up its lead drug for non-small cell lung cancer.

AstraZeneca adds Lilly to its stable of immuno-oncology collaborators

AstraZeneca believes the brightest future for its top oncology prospect will come through collaboration, recruiting Eli Lilly to its growing ranks of partners with eyes on kicking off a combination cancer trial.

Happy anniversary? Taking stock at Pfizer, AstraZeneca one year after the mega-mega-deal collapse

One year ago, Pfizer finally bowed out of the fight to buy AstraZeneca. The hostile bid was, well, quite hostile. And ever since, both companies have operated in the shadow of that failed deal.

AZ, Daiichi sign up Olympian Joyner-Kersee, hoping OIC patients will make tracks to Movantik

When you're targeting an under-the-radar malady that hasn't traditionally been treated with prescription drugs, it's up to marketers to get the word out and deliver on sales. And that's why AstraZeneca and Daiichi Sankyo, whose Movantik launched earlier this year, are bringing a 6-time Olympic medalist on board to talk about opioid-induced constipation (OIC).